Prestige BioPharma Limited
Prestige BioPharma Limited, a biopharmaceutical company, engages in the research and development and marketing of biosimilars, antibody drugs, and vaccines in Singapore. The company offers Trastuzumab biosimilar for the treatment of breast cancer; Bevacizumab biosimilar for the treatment in oncology; and PBP1502, an adalimumab biosimilar, which is in Phase 1 clinical trial for the treatment in im… Read more
Market Cap & Net Worth: Prestige BioPharma Limited (950210)
Prestige BioPharma Limited (KO:950210) has a market capitalization of $399.76 Million (₩585.34 Billion) as of March 18, 2026. Listed on the KO stock exchange, this Korea-based company holds position #24676 globally and #1453 in its home market, demonstrating a -2.79% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Prestige BioPharma Limited's stock price ₩9740.00 by its total outstanding shares 60096155 (60.10 Million).
Prestige BioPharma Limited Market Cap History: 2026 to 2026
Prestige BioPharma Limited's market capitalization history from 2026 to 2026. Data shows growth from $399.76 Million to $399.76 Million (0.00% CAGR).
Prestige BioPharma Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Prestige BioPharma Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
No P/S ratio data available
Latest Price to Earnings (P/E) Ratio
No P/E ratio data available
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| No financial ratio data available | |||||
Competitor Companies of 950210 by Market Capitalization
Companies near Prestige BioPharma Limited in the global market cap rankings as of March 18, 2026.
Key companies related to Prestige BioPharma Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Prestige BioPharma Limited Historical Marketcap From 2026 to 2026
Between 2026 and today, Prestige BioPharma Limited's market cap moved from $399.76 Million to $ 399.76 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩399.76 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Prestige BioPharma Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $399.76 Million USD |
| MoneyControl | $399.76 Million USD |
| MarketWatch | $399.76 Million USD |
| marketcap.company | $399.76 Million USD |
| Reuters | $399.76 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.